[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0480ee131a5655aa2cd1a97a83848c98215c62f68f52c6cdc2e2cccef4ed5f3d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734540120,
      "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "id": 132148536,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0480ee131a5655aa2cd1a97a83848c98215c62f68f52c6cdc2e2cccef4ed5f3d"
    }
  },
  {
    "ts": null,
    "headline": "GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer",
    "summary": "Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.",
    "url": "https://finnhub.io/api/news?id=95be068fd41508d350aff3f94026676ebaf3bc0082f74eba41dabb656371162c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734534840,
      "headline": "GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer",
      "id": 132040765,
      "image": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.",
      "url": "https://finnhub.io/api/news?id=95be068fd41508d350aff3f94026676ebaf3bc0082f74eba41dabb656371162c"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains",
    "summary": "GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.",
    "url": "https://finnhub.io/api/news?id=fc10686f69a3b951a15d97d3358a397ef18bcad2457c936da3f1e9be390c8bff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734531780,
      "headline": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains",
      "id": 132040766,
      "image": "https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.",
      "url": "https://finnhub.io/api/news?id=fc10686f69a3b951a15d97d3358a397ef18bcad2457c936da3f1e9be390c8bff"
    }
  },
  {
    "ts": null,
    "headline": "Gilead, Terray Therapeutics announce research collaboration",
    "summary": "Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray’s tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets se",
    "url": "https://finnhub.io/api/news?id=5c669ed52509dee4aa07677929facafb7d678c82626e7df5f19ce8aacbcf027b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734524449,
      "headline": "Gilead, Terray Therapeutics announce research collaboration",
      "id": 132040767,
      "image": "https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray’s tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets se",
      "url": "https://finnhub.io/api/news?id=5c669ed52509dee4aa07677929facafb7d678c82626e7df5f19ce8aacbcf027b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead and Terray link to develop small-molecule therapies",
    "summary": "Terray is set to leverage its platform to identify and develop compounds for targets chosen by Gilead.",
    "url": "https://finnhub.io/api/news?id=c3772f53f83a434ed7f9aae160188d2d3b3af807c28fb0d612c383c545ed7636",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734523095,
      "headline": "Gilead and Terray link to develop small-molecule therapies",
      "id": 132040768,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-2-Gilead-Terry-Shutterstock_2483231331.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Terray is set to leverage its platform to identify and develop compounds for targets chosen by Gilead.",
      "url": "https://finnhub.io/api/news?id=c3772f53f83a434ed7f9aae160188d2d3b3af807c28fb0d612c383c545ed7636"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. - U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer",
    "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with...",
    "url": "https://finnhub.io/api/news?id=55a9274b0cb17c7a2322a47bd594a7483b09d5eb6d981abf8ea6f86a441b792b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734517878,
      "headline": "Gilead Sciences, Inc. - U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer",
      "id": 132039374,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with...",
      "url": "https://finnhub.io/api/news?id=55a9274b0cb17c7a2322a47bd594a7483b09d5eb6d981abf8ea6f86a441b792b"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys",
    "summary": "Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.",
    "url": "https://finnhub.io/api/news?id=1622bfcd6476b1f6935d84f1ad53065555594e875fe18e2d92fb59ae55233c0a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734509400,
      "headline": "My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys",
      "id": 132038523,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.",
      "url": "https://finnhub.io/api/news?id=1622bfcd6476b1f6935d84f1ad53065555594e875fe18e2d92fb59ae55233c0a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure",
    "summary": "Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential for consistent revenue growth. See more.",
    "url": "https://finnhub.io/api/news?id=b237c2d257a7a4b8c3d3e77ff17c19432a5e5c088c757b0796b963b5794c0900",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734486818,
      "headline": "Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure",
      "id": 132036287,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395424723/image_1395424723.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential for consistent revenue growth. See more.",
      "url": "https://finnhub.io/api/news?id=b237c2d257a7a4b8c3d3e77ff17c19432a5e5c088c757b0796b963b5794c0900"
    }
  }
]